Revolution Medicines' Rasonque improves survival across pancreatic cancer subgroups in Phase 3 trial

• Revolution Medicines presented exploratory Phase 3 RASolute 302 subgroup results for Rasonque (daraxonrasib) at ESMO on October 23, 2026.
• Rasonque improved overall survival versus chemotherapy across evaluated tumor RAS profiles in previously treated metastatic pancreatic cancer, including patients without identified RAS mutations.
• The survival benefit persisted across chemotherapy regimens and prior treatment settings, including early metastatic recurrence following perioperative therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230730PRIMZONEFULLFEED9851531) on October 23, 2026, and is solely responsible for the information contained therein.